Antiviral treatments reduce severity of diabetes in Ljungan virus-infected CD-1 mice and delay onset in diabetes-prone BB rats

Microbiology and Immunology
Rebecka HolmbergB Niklasson

Abstract

The effects of LV in two different species, CD-1 mice, without a genetic disposition for diabetes, and BB rats prone to T1D were examined. Male CD-1 mice that had been exposed to LV in utero developed a type 2-like diabetes with increased blood glucose, insulin levels and epididymal fat at the age of 10-15 weeks. Combination therapy including LV-antiserum and an antiviral drug, Pleconaril, significantly reduced the levels of blood glucose and insulin and the amount of abdominal fat. In BB rats, LV has been found in both prediabetic- and diabetic diabetes-prone rats, as well as in diabetes-resistant rats. To evaluate whether the presence of LV has any influence on the onset of T1D, prediabetic BB rats were treated with an antiserum against LV or a combination of the antiviral drugs Pleconaril and Ribavirin. In the group treated with antiviral drugs, the onset was significantly delayed. These results indicate that the presence of LV can be involved in the pathogenesis of diabetes in these animal models.

References

May 24, 1979·The New England Journal of Medicine·J W YoonA L Notkins
Dec 1, 1991·The American Journal of Tropical Medicine and Hygiene·B NiklassonE Tkachenko
Sep 13, 1969·British Medical Journal·D R GambleK W Taylor
Jan 1, 1983·Scandinavian Journal of Infectious Diseases·B NiklassonJ Dalrymple
Sep 3, 1999·Antimicrobial Agents and Chemotherapy·D C PevearJ M Groarke
Feb 15, 2001·Expert Opinion on Investigational Drugs·J R Romero
Jan 15, 2003·Journal of Medical Virology·Taina HärkönenMerja Roivainen
Mar 12, 2003·Pharmacotherapy·Naomi R FloreaDavid P Nicolau
May 15, 2003·International Journal of Experimental Diabesity Research·Tonny FreimanisMogens Bildsøe
May 15, 2003·International Journal of Experimental Diabesity Research·B NiklassonAke Lernmark
Feb 11, 2004·Clinical & Developmental Immunology·Jan-Luuk HillebrandsJan Rozing
Feb 11, 2004·Clinical & Developmental Immunology·Nienke van der WerfJan Rozing
Nov 16, 2005·Reviews in Medical Virology·Jason D Graci, Craig E Cameron
Aug 9, 2006·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Annika SamsioeB Niklasson
Apr 5, 2007·Diabetologia·B NiklassonWilliam Klitz
Aug 22, 2007·Neuroimmunomodulation·Anneli Sepa, Johnny Ludvigsson

Citations

Jul 9, 2011·Journal of Medical Virology·B Niklasson
Oct 5, 2010·Birth Defects Research. Part A, Clinical and Molecular Teratology·Henry F Krous, Neil E Langlois
Aug 10, 2016·Viral Immunology·B NiklassonWilliam Klitz
Dec 8, 2010·Expert Review of Anti-infective Therapy·Joanne G WildenbeestKatja C Wolthers

Related Concepts

Picovir
Antibodies, Viral
Antiviral Agents
Diabetes, Autoimmune
Polychemotherapy
Oxadiazoles
Picornaviridae Infections
Rats, Inbred BB
Ribasphere
Parechovirus

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Birth Defects Research. Part B, Developmental and Reproductive Toxicology
Annika SamsioeWilliam Klitz
Birth Defects Research. Part A, Clinical and Molecular Teratology
B NiklassonWilliam Klitz
Forensic Science, Medicine, and Pathology
B NiklassonWilliam Klitz
Birth Defects Research. Part A, Clinical and Molecular Teratology
Annika SamsioeB Niklasson
© 2021 Meta ULC. All rights reserved